Rtw Investments 13F: Cuts Zai Lab (ZLAB) Stake by $7.3M

RTW Investments has adjusted its portfolio by trimming its stake in Zai Lab Limited (NasdaqGM: ZLAB). The fund reduced its holdings by 385,000 shares, a 5.5% decrease, bringing its total to 6,574,032 shares valued at approximately $112.2 million. This change was disclosed in a recent Form 13F filing, reflecting the fund's position as of the end of the reporting period.

What Changed in RTW Investments' Zai Lab Position

RTW Investments' decision to cut its stake in Zai Lab Limited involved selling 385,000 shares, reducing its holdings by 5.5% from the previous count of 6,959,032 shares. The updated position consists of 6,574,032 shares valued at around $112.2 million.

Other Institutional Activity in Zai Lab Limited

RA Capital Management added a significant number of shares, now holding 5,707,262 shares valued at $107.4 million. Frazier Life Sciences Management maintained its position with 1,902,320 shares worth about $35.8 million. Citadel Advisors made a minor increase of 786 shares, resulting in a total of 1,688,632 shares valued at $31.8 million. BAMCO Inc increased its holdings by 240,313 shares, bringing its total to 1,658,318 shares worth approximately $31.2 million. Lastly, ADAR1 Capital Management added 178,847 shares, now holding 1,425,367 shares valued at $26.8 million.

Zai Lab Limited Stock Down 26.1%

Shares of Zai Lab Limited (NasdaqGM: ZLAB) are trading at $17.07. The company has a market cap of $1.92 billion and a forward P/E ratio that suggests it's not currently profitable. Its beta is 0.781, indicating lower volatility compared to the market. The stock's 52-week range is between $15.96 and $41.20, with a 50-day moving average of $20.07 and a 200-day moving average of $22.11.

Recent Earnings

Zai Lab reported revenues of $453.3 million, though revenue growth showed a decline of 6.5%. The company posted a net margin of -39.3% and a return on equity of -24.2%. The next earnings report is scheduled for August 6, 2026.

Insider Buying and Selling at Zai Lab Limited

On May 11, 2026, Operating Partner Wang Yizhe made two purchases totaling 196,107 shares. CEO Dr. Ying Du was active with multiple transactions: on May 19, she bought 261,092 shares at $1.74, and sold 117,435 shares at $18.75. On May 26 and 27, she sold additional shares totaling 107,700.

Analysts Set New Price Targets

On May 8, 2026, Citigroup maintained a 'buy' rating on Zai Lab with a price target of $44. JP Morgan also kept a 'buy' rating with a $32 target on March 18, 2026. Overall, analysts hold a strong buy consensus with a mean target price of $33.30 based on 12 opinions.

About Zai Lab Limited

Zai Lab Limited is a biopharmaceutical company based in Pudong, China. It focuses on developing and commercializing treatments in oncology, immunology, neuroscience, and infectious diseases. The company's portfolio includes products like Zejula for ovarian cancer and VYVGART for myasthenia gravis. Led by CEO Dr. Ying Du, the company employs 1,784 people and collaborates with several global pharmaceutical firms.

Bottom Line

RTW Investments' recent reduction in its Zai Lab stake reflects strategic portfolio management. Investors track such filings for insights into fund strategies, though they are backward-looking and may not indicate current positions. Zai Lab continues to be a focus for analysts and insiders, with strong buy ratings and active trading from company executives.